| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300511 | 雪橙生物 | 6.27 | 4.85% | 38.70万 | | 2.40亿 | | 600313 | 农发种业 | 8.25 | 4.04% | 261.66万 | | 21.21亿 | | 002215 | 诺普信 | 11.49 | 3.42% | 27.24万 | | 3.10亿 | | 600883 | 博闻科技 | 8.75 | 1.98% | 7.45万 | 6483.37万 | | | 600359 | 新农开发 | 7.52 | 0.94% | 21.65万 | | 1.62亿 | | 000998 | 降平高科 | 10.12 | 0.80% | 72.43万 | | 7.35亿 | | 300970 | 华绿生物 | 22.14 | 0.68% | 4.28万 | 9495.88万 | | | 600540 | 新塞股份 | 4.97 | 0.61% | 14.17万 | 7002.33万 | ...

证券日报网讯2月2日，华绿生物（300970）在互动平台回答投资者提问时表示，公司主要从事食用菌的 研发、种植和销售。 ...

证券之星消息，1月29日种植业板块较上一交易日上涨2.94%，海南橡胶领涨。当日上证指数报收于 4157.98，上涨0.16%。深证成指报收于14300.08，下跌0.3%。种植业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 601118 | 海南橡胶 | 7.84 | 9.96% | 234.81万 | | 17.72亿 | | 300189 | 神农种业 | 7.67 | 8.33% | 339.19万 | | 25.61亿 | | 920087 | 秋乐种业 | 19.08 | 7.31% | 18.96万 | | 3.54亿 | | 600313 | 农发种业 | 8.03 | 6.36% | 256.63万 | | 20.33亿 | | 920403 | 康农种业 | 27.14 | 3.39% | 7.81万 | | 2.13亿 | | 600598 | 北大荒 | 16.87 | 2.80% | 97.39万 | | 16.42亿 | | 3 ...

根据公告，2025年归母净利润（扣非相同）1.0-1.3e，同比大幅扭亏；其中单Q4 利润 0.84-1.14e，均值1.0e，同比 大幅扭亏，环比增长40%+，收入端同比平均也有45%+增速。 从报表可以看到，行业高景气度毋庸置疑，公司稳健踏实，不存在雷，只会超预期。 #华绿生物 2025年度业绩预告：#超预期，印证产业逻辑 #华绿生物 2025年度业绩预告：#超预期，印证产业逻辑 根据公告，2025年归母净利润（扣非相同）1.0-1.3e，同比大幅扭亏；其中单Q4 利润 0.84-1.14e，均值1.0e，同比 大幅扭亏，环比增长40%+，收入端同比平均也有45%+增速。 这还是25年公司加大奖金费用支出后的报表业绩，非常亮眼！ 这还是25年公司加大奖金费用支出后的报表业绩，非常亮眼！ 从报表可以看到，行业高景气度毋庸置疑，公司稳健踏实，不存在雷，只会超预期。 ...

经济观察网2026年1月20日，华绿生物（300970）发布2025年度业绩预告，预计2025年净利润1亿元至 1.3亿元，同比增长310.24%至373.31%；扣除非经常性损益后的净利润1亿元至1.3亿元，同比增长 306.25%至368.13%。 ...

Group 1: Delisting Risks - *ST Xin Yan: The Shenzhen Stock Exchange has approved the company's application to revoke the delisting risk warning due to restructuring [1] - *ST Zhong Zhuang (Rights Protection): The delisting risk warning has been revoked, but other risk warnings will continue, and the stock will be suspended for one day starting tomorrow [2] - ST Sai Wei: Expected to incur a loss of 720 million to 1.02 billion yuan in 2025, with a possibility of being subject to delisting risk warnings [3] Group 2: Earnings Forecasts - Hikvision: Expected net profit attributable to shareholders to grow by 18.46% year-on-year in 2025 [28] - Langzi Co.: Expected net profit to increase by 245.25% to 302.8% year-on-year in 2025 [4][30] - Zhaoyan New Drug: Expected net profit to increase by 214% to 371% year-on-year in 2025 [5][30] - Huachen Equipment: Expected net profit to increase by 193.64% to 242.04% year-on-year in 2025 [6][30] - Qianyuan Power: Expected net profit to increase by 160% to 190% year-on-year in 2025 [7][30] - Jin Fang Energy: Expected net profit to increase by 123.97% to 193.7% year-on-year in 2025 [8][31] - Zhongfu Industrial: Expected net profit to increase by 120.27% to 141.59% year-on-year in 2025 [9][32] - Batian Co.: Expected net profit to increase by 117.53% to 139.53% year-on-year in 2025 [10][32] - Zhongrong Electric: Expected net profit to increase by 104.89% to 131.10% year-on-year in 2025 [11][32] - Kaisheng New Materials: Expected net profit to increase by 96.47% to 150.06% year-on-year in 2025 [12][32] - Putailai: Expected net profit to increase by 93.18% to 101.58% year-on-year in 2025 [13][32] - Dongfang Iron Tower: Expected net profit to increase by 91.4% to 125.07% year-on-year in 2025 [14][32] - Pulaike: Expected net profit to increase by 89.64% to 110.11% year-on-year in 2025 [15][32] - Huabang Health: Expected profit of 660 million to 730 million yuan in 2025, turning from loss to profit [16][32] - Hongyuan Green Energy: Expected net profit of 180 million to 250 million yuan in 2025, turning from loss to profit [17][32] - Kangda New Materials: Expected profit of 125 million to 135 million yuan in 2025, turning from loss to profit [18][32] - Langxin Technology: Expected profit of 100 million to 150 million yuan in 2025, turning from loss to profit [19][32] - Hualv Biological: Expected profit of 100 million to 130 million yuan in 2025, turning from loss to profit [20][32] Group 3: Mergers and Acquisitions - Kangxin New Materials: Plans to acquire 51% of Yubang Semiconductor for 392 million yuan [21][32] - Aibo Medical: Plans to gain control of Demei Medical [22][32] Group 4: Share Buybacks and Reductions - Hengtong Co.: Plans to repurchase company shares worth 80 million to 100 million yuan [24][32] - Haier Smart Home: Plans to repurchase D shares up to 200,000 euros [29][32] - Blue Universe Co.: Shareholders plan to reduce their holdings by no more than 3.02% [29][32] - Hesheng Silicon Industry: Controlling shareholder plans to reduce holdings by no more than 3% [29][32] - Aolian Electronics (Rights Protection): Shareholder Liu Junsheng plans to reduce holdings by no more than 3% [29][32] - Bluefeng Biochemical: Hainan Wenqin plans to reduce holdings by no more than 3% [29][32] - Zhixin Precision: Shareholders plan to reduce holdings by no more than 3% [29][32] - Peking University Medical: Peking University Health plans to reduce holdings by no more than 3% [29][32] Group 5: Other Updates - Liou Co.: Self-inspection work has been completed, and the stock will resume trading on January 21 [29][32] - Yongxing Materials: The lithium mica green intelligent and efficient lithium extraction project has reached production capacity [29][32] - Debang Co.: Plans to voluntarily withdraw A shares from trading on the Shanghai Stock Exchange [29][32]

Group 1: Earnings Forecasts - Huabang Health expects a net profit of 660 million to 730 million yuan for 2025, recovering from a loss of 299 million yuan in the previous year, driven by improvements in its agricultural chemical materials sector and steady growth in its pharmaceutical and tourism segments [2] - Kangda New Materials anticipates a net profit of 125 million to 135 million yuan for 2025, compared to a loss of 246 million yuan last year, primarily due to significant sales growth in adhesive and specialty resin products, particularly in the wind power sector [2] - Longxin Technology forecasts a net profit of 100 million to 150 million yuan for 2025, recovering from a loss of 250 million yuan, with improvements in its energy digitalization business and reduced losses in its new energy sector [3] - Hualu Bio expects a net profit of 100 million to 130 million yuan for 2025, recovering from a loss of 47.57 million yuan, attributed to increases in both sales price and volume [3] - Jiuxi Software predicts a net profit of 40 million to 60 million yuan for 2025, recovering from a loss of 156 million yuan, supported by AI technology enhancements and market expansion strategies [3] Group 2: Major Corporate Developments - Liou Co. has completed its stock suspension review and will resume trading on January 21, 2026, confirming that its business operations remain normal and no significant undisclosed matters exist [4] - Hikvision reported total revenue of 92.518 billion yuan for 2025, a slight increase of 0.02%, with a net profit of 14.188 billion yuan, up 18.46%, driven by strategic adjustments and improved cash flow management [6] - JianTou Energy expects a net profit of approximately 1.877 billion yuan for 2025, a significant increase of about 253.38% from the previous year, due to optimized coal resource allocation and cost management [6] Group 3: Investment and Mergers - Aibo Medical plans to acquire at least 51% of Demai Medical to gain control, aiming to leverage its R&D advantages in the sports health sector [19] - Yifan Transmission intends to purchase 87.07% of Beijing Helishi Motor Technology Co., which will become a subsidiary upon successful completion of the transaction [16] - Guangdong Hongtu plans to invest up to 95 million yuan to establish a subsidiary in Thailand for automotive parts production and sales [20] Group 4: Stock Performance and Changes - Huicheng Environmental's major shareholder plans to increase their stake in the company by investing between 25 million and 50 million yuan within six months [22] - Liou Co. will resume trading after completing its stock suspension review, indicating stability in its operations [24] - Kailong High-Tech and Debang Co. have been suspended from trading, indicating potential issues or developments requiring further clarification [25]

1．财政部副部长廖岷在国新办新闻发布会上表示，财政部门将继续实施更加积极的财政政策。概括起 来就是"总量增加、结构更优、效益更好、动能更强"。2026年财政赤字、债务总规模和支出总量将保持 必要水平，确保总体支出力度只增不减。 2.财政部副部长廖岷在国新办新闻发布会上表示，本次优化调整个人消费贷款贴息政策，将信用卡账单 分期业务纳入到了贴息范围，取消现有政策当中对一些消费领域的限制。新政策意味着只要是消费贷款 都可以享受贴息。 重要的消息有哪些 1月21日（周三）申购提示 新股方面，美德乐申购代码920119，发行价格41.88元/股 ，发行市盈率为14.99倍，单一账户申购上限为 72万股。 投资有风险，申购需谨慎。 4.财政部等部门发布关于延续实施养老、托育、家政等社区家庭服务业税费优惠政策的公告，为社区提 供养老、托育、家政等服务的机构，按照规定享受税费优惠政策。 3.财政部综合司司长李先忠在国新办新闻发布会上表示，近期财政部、税务总局发布公告，明确自2026 年4月1日起取消光伏等产品出口退税，并分两年取消电子产品出口退税。此次出口退税政策调整，有利 于促进资源高效利用，也有利于引导产业结构合理调整， ...

北京商报讯（记者 郭秀娟 王悦彤） 1月20日，华绿生物发布公告称，公司预计2025年度实现归母净利 润12亿元至14亿元，比上年同期增长16.27%至35.64%。 公司业绩的提升主要得益于销售单价与销售量的同步增长。一方面，食用菌行业经过长期调整后，于 2025年下半年企稳回暖，市场行情向好推动公司主要产品价格进入上升通道；另一方面，公司产能扩大 带动销售量增加，上述因素综合影响使公司毛利率提高，净利润较去年同期大幅增长并实现扭亏为盈。 ...

证券日报网讯 1月20日，华绿生物在互动平台回答投资者提问时表示，公司产品以产定销，每日产量会 有波动。 （文章来源：证券日报） ...